Immunobiology of Cancer
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 84
- 试验地点
- 1
研究概览
简要总结
To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.
详细描述
BACKGROUND
We have previously demonstrated that tumor-specific T cells could be identified in >50% of patients with metastatic melanoma and these cells appeared to be rendered anergic in vivo [Nature Medicine 5:677, 1999]. Recently we discovered that there is a signaling defect in the Interferon (IFN) pathway in immune cells from melanoma patients [PLOS Medicine 4:897 2007]. Interestingly, preliminary studies are showing the same defect in immune cells from breast cancer patients (unpublished). We would like to expand our research to all types of cancer to determine whether these phenomena occur in different cancer types.
OBJECTIVES
Our primary objective is to determine whether there is an IFN signaling defect in different types of cancers and to determine what is causing this defect.
The second objective is to determine whether these PBMCs are rendered anergic.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who have cancer or participants who do not have cancer and/or an autoimmune disorder and are age 18 or over.
排除标准
- •Participants who have an autoimmune disorder and/or are under the age of 18 years.